Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jan-Dec:54:19160216251330629.
doi: 10.1177/19160216251330629. Epub 2025 Apr 15.

Pooled Analysis of 2 Randomized Clinical Trials to Evaluate the Efficacy and Safety of Clotrimazole 1% Otic Solution for the Treatment of Otomycosis in Adults

Ansley J F  1 , Bernal-Sprekelsen M  2 , Butehorn H F  3 , Todorov S  4 , Tzvetkov V  5 , Douglis F  6 , Georgiev K  7 , Moreira da Silva F  8
Affiliations
Randomized Controlled Trial

Pooled Analysis of 2 Randomized Clinical Trials to Evaluate the Efficacy and Safety of Clotrimazole 1% Otic Solution for the Treatment of Otomycosis in Adults

Ansley J F et al. J Otolaryngol Head Neck Surg. 2025 Jan-Dec.

Abstract

ImportanceThere is no antifungal otic drug for the treatment of otomycosis approved in the United States. Some current clotrimazole formulations in the market are used off-label.ObjectiveTo evaluate the efficacy and safety of clotrimazole 1% otic solution compared to placebo in treating otomycosis in adults.DesignTwo independent twin multicenter, randomized (2:1), double-blind, controlled clinical trials with identical designs were conducted from February 2020 to October 2021.SettingFifty-three sites located in the United States, Mexico, and Europe.ParticipantsAdults with uncomplicated otomycosis presented with symptoms, debris, and drainage clinically consistent with fungal infection.InterventionPatients received clotrimazole or placebo twice daily for 14 days and were evaluated on visit 1 (day 1), visit 2 (day 8-10), visit 3 (day 15), and follow-up visit 4 (day 24-26).Main Outcome MeasuresAt each visit, pruritus, otalgia, otorrhea, and ear fullness were assessed. Ear exudate was taken for a mycological and microbiological evaluation at baseline and, if present, at subsequent visits. The primary endpoint was a therapeutic cure (mycological and clinical) at visit 4 in the randomized population with positive fungal culture at baseline [mycological intent-to-treat (MITT)].ResultsThree hundred ninety-three patients received study medication (261 clotrimazole and 132 placebo). Efficacy data from the 228 patients (157 clotrimazole and 71 placebo) included in the MITT were analyzed. The clotrimazole group achieved a higher proportion for the primary endpoint than those with the placebo group (68.2% vs 25.4%; P < .0001), with a 42.8 difference in response rate (95% confidence interval: 30.3, 55.3). The treatment was safe and well tolerated, with 2.7% of related adverse events in the clotrimazole versus 1.5% in the placebo group.ConclusionsClotrimazole 1% otic solution has demonstrated its superiority over the placebo in each study and the pooled analysis. These are the results of the first international, multicenter clinical trials in which clotrimazole 1% otic solution demonstrates efficacy for the treatment of otomycosis.

Keywords: antifungal; clotrimazole; otic solution; otomycosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ansley J.F., Butehorn H.F., Todorov S., Tzvetkov V., Douglis F., Georgiev K., Moreira da Silva F.: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.Bernal-Sprekelsen: The author declared speaker honorarium for GSK Spain, Sanofi Spain, Consultant for Bionorica Germany.

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Patient flow.
Figure 2.
Figure 2.
Percentage of patients with each sign and symptom over time (MITT population). MITT, mycological intent-to-treat.
Figure 3.
Figure 3.
Mean value of total signs and symptoms score changes over time (MITT population). MITT, mycological intent-to-treat.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Westby D, O’Connell N, Powell J, Fenton JE. The changing nature of paediatric otomycosis in the mid-west of Ireland. J Laryngol Otol. 2020;134(7):592-596. doi:10.1017/S0022215120001164 - DOI - PubMed
    1. Khan F, Muhammad R, Khan MR, et al. Efficacy of topical clotrimazole in treatment of otomycosis. J Ayub Med Coll Abbottabad. 2013;25(1-2):78-80. - PubMed
    1. Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol. 2008;72(4):453-459. doi:10.1016/j.ijporl.2007.12.005 - DOI - PubMed
    1. Haq M, Deshmukh P. Review of recurrent otomycosis and clotrimazole in its treatment. Cureus. 2022;14(10):e30098. doi:10.7759/CUREUS.30098 - DOI - PMC - PubMed
    1. Salvat. SVT-15652 Otic Solution for the Treatment of Otomycosis NCT03686384. U.S. National Library of Medecine. Published 2021. Accessed July 26, 2023. https://www.clinicaltrials.gov/study/NCT03686384?term=SVT-15652&cond=Oto...

Publication types

LinkOut - more resources